Oncology News | pharmaphorum

News

Carvykti, Abecma move earlier in multiple myeloma treatment

Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR-T therapy Carvykti has been approved by the FDA to treat patients with multiple myeloma after at least one pri

News

CRUK gives £58m funding for clinician scientist training

Cancer Research UK has announced a major initiative to train more doctors as clinician scientists that can contribute to research into new cancer treatments.

News

ADRIATIC buoys Imfinzi’s prospects in early lung cancer

After a setback in a trial of Imfinzi in early non-small cell lung cancer (NSCLC) last year, AstraZeneca has clawed back some ground with a positive result in small-cell l

News

Merck taps Caris’ AI expertise in ADC-focused alliance

Germany’s Merck KGaA has partnered with techbio company Caris Discovery in a $1.4 billion alliance that will apply artificial intelligence to the design of antibody-drug c

News

Aardvark said to be planning IPO, plus other bio financings

Our regular round-up of financings in the biotech sector is headed by rumours of a $150 to $200 million initial public offering (IPO) for Aardvark Therapeutics, an emergin

News

Genmab offers $1.8bn for ADC specialist ProfoundBio

Antibody developer Genmab has made a play to boost its expertise in the scalding hot area of antibody-drug conjugates (ADCs), agreeing a $1.8 billion deal to acquire Profo

Carvykti, Abecma move earlier in multiple myeloma treatment

CRUK gives £58m funding for clinician scientist training

ADRIATIC buoys Imfinzi’s prospects in early lung cancer

Merck taps Caris’ AI expertise in ADC-focused alliance

Aardvark said to be planning IPO, plus other bio financings

Genmab offers $1.8bn for ADC specialist ProfoundBio

On genomics, NGS, and doing much more good than bad, with Ma...

How to meet your physicians where they are online

News

Editor's Picks